Halozyme Therapeutics, Inc. — Q2 2013 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2013. Halozyme is a clinical-stage biopharmaceutical company with one marketed product, Hylenex recombinant, and collaboration and development programs primarily using rHuPH20 technology. Unless noted, comparisons are with the corresponding 2012 period.
Financial results
| Metric | Q2 2013 | Q2 2012 | Six months 2013 | Six months 2012 |
|---|---|---|---|---|
| Total revenue | $14.45 million | $7.76 million | $26.29 million | $15.20 million |
| Net loss | $22.91 million | $14.02 million | $42.20 million | $29.14 million |
| Net loss per share | $0.20 | $0.13 | $0.38 | $0.27 |
| Operating cash used | — | $21.71 million | $33.11 million |
- Q2 product sales were $3.10 million, including $1.1 million of rHuPH20 API sales for HyQvia; collaboration revenue was $11.35 million. Six-month product sales were $4.61 million and collaboration revenue was $21.68 million.
- Q2 operating expenses rose to $36.57 million from $21.81 million, led by R&D of $27.99 million versus $16.08 million. The operating loss was $22.12 million versus $14.05 million. Product cost included a $0.6 million inventory write-off.
- At June 30, cash and cash equivalents were $27.93 million and marketable securities were $48.08 million, totaling approximately $76.01 million. Total current assets were $100.42 million and current liabilities $32.83 million. Stockholders’ equity was $11.14 million, down from $48.85 million at year-end 2012.
- Long-term debt had a carrying amount of approximately $29.72 million, including current maturities. The $30 million secured loan bears 7.55% fixed interest and matures January 1, 2017; the company reported compliance with material covenants.
- Operating cash use declined year over year, partly due to collecting receivables and deferring payment of incurred expenses. Investing activities used $49.56 million, mainly for marketable securities; cash declined by $71.57 million during the six months.
Material changes and business developments
- Revenue increased substantially, principally from higher Roche collaboration reimbursements and increased Hylenex sales; the prior-year six-month period included a $4 million Roche milestone that was absent in 2013.
- R&D and SG&A spending increased as the company expanded clinical, manufacturing and commercial activities. Management attributed much of the R&D increase to manufacturing support for potential collaboration launches and trials, including insulin and PEGPH20 programs.
- In May 2013, HyQvia received European Commission marketing authorization. Baxter launched it in its first EU country in July; the first commercial sale triggered a $4 million payment to Halozyme, expected to be recognized in Q3 2013.
- Roche’s subcutaneous Herceptin received a positive recommendation from the EMA committee in June. Halozyme also reported encouraging interim PEGPH20 Phase 1b results and commencement of a Phase 2 pancreatic cancer study.
Outlook, risks and contingencies
- Management forecast 2013 net cash burn of approximately $45–$50 million, dependent on clinical progress, manufacturing scale-up, and collaboration milestones and royalties. It expected existing cash and cash equivalents to fund operations for at least 12 months, but did not expect revenue to fund operations before 2014 at the earliest. Additional financing may be needed; availability and terms are uncertain.
- Management expected R&D and commercial spending to increase in 2013. Collaboration reimbursements and other non-reimbursement revenue may fluctuate with partner activity and milestone achievement.
- The FDA had issued a complete response letter for Baxter’s U.S. HyQvia application, requesting additional preclinical data concerning non-neutralizing anti-rHuPH20 antibodies and potential reproductive, developmental and fertility effects. ViroPharma discontinued its Phase 2 subcutaneous Cinryze study as a precaution after unexpected antibody incidence and titers; no associated adverse clinical effects had been reported. These developments create regulatory and platform risks.
- Other key risks include clinical-trial failure or delay, reliance on collaborators and contract manufacturers, regulatory approval and commercialization uncertainty, competition, and possible need for dilutive or debt financing. The company reported no material legal proceedings and effective disclosure controls.
Most important facts for investors to verify
- Whether the $45–$50 million 2013 cash-burn outlook and stated liquidity runway remain achievable.
- Progress on FDA requirements for HyQvia and the implications of anti-rHuPH20 antibody findings across programs.
- HyQvia’s European launch uptake and recognition of the $4 million Baxter payment in Q3.
- Clinical and regulatory progress in PEGPH20, insulin, Roche subcutaneous products and other pipeline programs, alongside rising R&D costs.
- Debt service, financing needs, and the effect of continued losses on the company’s comparatively reduced equity balance.